Effect of a high-protein meal on gabapentin pharmacokinetics. 1996

B E Gidal, and M M Maly, and J Budde, and G L Lensmeyer, and M E Pitterle, and J C Jones
University of Wisconsin, School of Pharmacy, Madison 53706, USA.

The anticonvulsant gabapentin is transported across biological membranes via the L-amino acid transport system (System-L). Absorption of gabapentin is saturable, and in-vitro data have previously demonstrated that both L-leucine and L-phenylalanine may compete with the intestinal transport of gabapentin. The purpose of this study therefore was to determine whether a high-protein meal would interfere with gabapentin absorption. Ten healthy volunteers received in a randomized, cross-over design, a single 600-mg dose of gabapentin in the fasting state and after a high-protein meal consisting of 80 gm total protein (4.1 g phenylalanine, 8.2 g leucine and 4.2 g isoleucine), 52 g carbohydrate, and 9 g fat. Plasma gabapentin concentrations were measured by HPLC at baseline, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 30 h. Calculated pharmacokinetic parameters included Cmax' Tmax' AUC and T1/2. In addition, a pharmacodynamic assessment (using visual analog scales) of gabapentin-related adverse effects was performed at 2 h post drug ingestion and was compared between study phases. Statistical analysis included Student's t-test for paired data, with significance assigned at P < 0.05. Cmax was significantly increased by 36% (3.87 +/- 1.15 vs 5.28 +/- .97 micrograms/ml, P = 0.002), and Tmax tended to be shorter (3.9 +/- 1.8 vs 2.8 +/- .35 h, P = 0.10), after the high-protein meal. Although AUC was increased by 11%, this did not achieve statistical significance. Despite significantly higher plasma concentrations at 2 h, subjects reported significantly fewer adverse effects after the high-protein meal. Potential mechanisms to explain these unexpected findings may be that the large amino acid load delivered with the high-protein meal enhanced gabapentin absorption via trans-stimulation, the process by which acutely increased intestinal luminal amino acid concentrations result in an acute up regulation in System-L activity. Conversely, the decrease in perceived adverse CNS effects of gabapentin following the high-protein meal may reflect CNS competition for System-L transport.

UI MeSH Term Description Entries
D008297 Male Males
D003509 Cyclohexanecarboxylic Acids Carboxylic acid derivatives of cyclohexane. Acids, Cyclohexanecarboxylic
D004044 Dietary Proteins Proteins obtained from foods. They are the main source of the ESSENTIAL AMINO ACIDS. Proteins, Dietary,Dietary Protein,Protein, Dietary
D004435 Eating The consumption of edible substances. Dietary Intake,Feed Intake,Food Intake,Macronutrient Intake,Micronutrient Intake,Nutrient Intake,Nutritional Intake,Ingestion,Dietary Intakes,Feed Intakes,Intake, Dietary,Intake, Feed,Intake, Food,Intake, Macronutrient,Intake, Micronutrient,Intake, Nutrient,Intake, Nutritional,Macronutrient Intakes,Micronutrient Intakes,Nutrient Intakes,Nutritional Intakes
D005260 Female Females
D005680 gamma-Aminobutyric Acid The most common inhibitory neurotransmitter in the central nervous system. 4-Aminobutyric Acid,GABA,4-Aminobutanoic Acid,Aminalon,Aminalone,Gammalon,Lithium GABA,gamma-Aminobutyric Acid, Calcium Salt (2:1),gamma-Aminobutyric Acid, Hydrochloride,gamma-Aminobutyric Acid, Monolithium Salt,gamma-Aminobutyric Acid, Monosodium Salt,gamma-Aminobutyric Acid, Zinc Salt (2:1),4 Aminobutanoic Acid,4 Aminobutyric Acid,Acid, Hydrochloride gamma-Aminobutyric,GABA, Lithium,Hydrochloride gamma-Aminobutyric Acid,gamma Aminobutyric Acid,gamma Aminobutyric Acid, Hydrochloride,gamma Aminobutyric Acid, Monolithium Salt,gamma Aminobutyric Acid, Monosodium Salt
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077206 Gabapentin A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME. 1-(Aminomethyl)cyclohexaneacetic Acid,Apo-Gabapentin,Convalis,Gabapentin Hexal,Gabapentin Stada,Gabapentin-Ratiopharm,Neurontin,Novo-Gabapentin,PMS-Gabapentin,Apo Gabapentin,ApoGabapentin,Gabapentin Ratiopharm,Novo Gabapentin,NovoGabapentin
D000085 Acetates Derivatives of ACETIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxymethane structure. Acetate,Acetic Acid Esters,Acetic Acids,Acids, Acetic,Esters, Acetic Acid
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

B E Gidal, and M M Maly, and J Budde, and G L Lensmeyer, and M E Pitterle, and J C Jones
October 1997, Epilepsia,
B E Gidal, and M M Maly, and J Budde, and G L Lensmeyer, and M E Pitterle, and J C Jones
June 1992, British journal of clinical pharmacology,
B E Gidal, and M M Maly, and J Budde, and G L Lensmeyer, and M E Pitterle, and J C Jones
October 2010, Journal of clinical pharmacology,
B E Gidal, and M M Maly, and J Budde, and G L Lensmeyer, and M E Pitterle, and J C Jones
March 1986, British journal of clinical pharmacology,
B E Gidal, and M M Maly, and J Budde, and G L Lensmeyer, and M E Pitterle, and J C Jones
May 2019, Clinical pharmacology in drug development,
B E Gidal, and M M Maly, and J Budde, and G L Lensmeyer, and M E Pitterle, and J C Jones
October 1989, Transplantation,
B E Gidal, and M M Maly, and J Budde, and G L Lensmeyer, and M E Pitterle, and J C Jones
December 2000, Pharmacological research,
B E Gidal, and M M Maly, and J Budde, and G L Lensmeyer, and M E Pitterle, and J C Jones
January 2000, European journal of drug metabolism and pharmacokinetics,
B E Gidal, and M M Maly, and J Budde, and G L Lensmeyer, and M E Pitterle, and J C Jones
February 2002, Pharmacotherapy,
B E Gidal, and M M Maly, and J Budde, and G L Lensmeyer, and M E Pitterle, and J C Jones
April 2014, Journal of clinical pharmacology,
Copied contents to your clipboard!